Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5414630 | 0.96 | CACNA1B (0.40) | KDM4EALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL4048452 | 0.91 | MEN1 (0.43) | KDM4EALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL4045889 | 0.88 | CACNA1B (0.43) | KDM4EALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL4044883 | 0.87 | CACNA1B (0.43) | KDM4EALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL5424122 | 0.86 | KDM4E (0.44) | KDM4EALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL5422453 | 0.85 | ALDH1A1 (0.50) | KDM4EALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL5425312 | 0.84 | ALDH1A1 (0.45) | KDM4EALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL4049133 | 0.81 | CACNA1B (0.44) | KDM4EALDH1A1MEN1KMT2AHDAC3 | |
| SCHEMBL4047988 | 0.78 | MAPT (0.41) | KDM4EALDH1A1HPGDTDP1L3MBTL1 | |
| SCHEMBL4043269 | 0.78 | KDM4E (0.44) | KDM4EALDH1A1MEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070173499-A1 | Use of benzonaphthoazulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O. (HR) | 2007-07-26 | — | — | US | claimed |
| EP-1708696-A1 | USE OF BENZONAPHTHOAZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | GlaxoSmithKline istrazivacki centar Zagreb d.o.o. (HR) | 2006-10-11 | — | — | EP | claimed |
| WO-2005072728-A1 | USE OF BENZONAPHTHOAZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2005-08-11 | — | — | WO | claimed |
| US-20070173499-A1 | Use of benzonaphthoazulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O. (HR) | 2007-07-26 | — | — | US | disclosed |
| EP-1114836-B1 | PROCESS FOR PRODUCING A RESIN COMPOSITION | NAT INST OF ADVANCED IND SCIEN (JP) | 2006-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173499-A1 | Use of benzonaphthoazulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders | BCHE, GAP43, DBH | KDM4E 1637/4885ALDH1A1 499/4885MEN1 1451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.